Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There could already be a framework of conditional agreements signed by one party based on different possibilities of FDA designations and ph2 results that are waiting for Mr. Ehrlich's signature after FDA designates. We just don't know as we are outsiders. But Mr. Ehrlich's tone changed from his note to Karin (Nov 2014) about not wanting to uplist for fear of dilution, to his statement at Jan 12 biotech conference about uplisting sometime in 2015, to Jan 24 (I believe) pursuing uplisting with legal council, to Feb 5 filing application.
Everyone entitled to negative opinions, but folks we are waiting on FDA designations and that is a key event along with ECCMID. Why is Leo uplisting..sounds encouraging to me...financial confidence and happy with B ph2 results. Some of the downer talk here exaggerates like things won't happen until Dec 32, 2015. Leo and Krishna are positioning us for better things down the road. IMHO
I'm long this stock. Understand the delay with BOM as part of B platform which may be part of a B platform deal which hinges on FDA go to phase 3 approval and uplisting. But why Prurisol phase 2 has not started makes no sense.
For now, I'm just taking the K June end time as the earliest possible completion time. They had to update as its been 6 months I believe. And they sure don't want to say Sept for completion date without news of a change in protocol like Big Kahuna was describing. <--- All IMHO.
Wondering when MTD is reached in Phase 1 if they can actually keep the Phase 1 open to do the 2-3 times per week dosing.
Yes Karin, your welcome. Hope Leo and Krishna keep you busy in 2015 and 2016 with more writings of good news.
Your work is truly admired. I read it three times as it was that good.
Not on that ride, but those who waited 4 years (even 3 years) made out quite well right now.
Do you know if its possible for Menon to put Kevetrin in an oral pill form down the road???
I'm sure as they said at BioShowCase they are fielding calls. The potential interested parties show interest by making initial bids known as round #1 and Leo tells them he will consider the current bid and any new bids in a round #2 after phase 3 starts. Then he lets bidders make a final bid against the highest bid of round #2. Highest bidder from this becomes a new business companion for ctix.
I do agree with you, this will not be strung out past early Fall as time is money and close the deal and good enough value obtained at this point. About that big pharma interested in B for biofilms, it sure feels IMO they are interested in other possible revenues from B indications which are more fruitful than the biofilm revenues.
We shall see how it all turns out. Exciting times ahead.
I was really hoping to hear about start of K combo trial at University of Bologna in February. Wonder if DF is slow in getting data prepared to the univ so they can start.
The most important thing now is to get the B phase 3 trial in progress along with a partnership/license for full funding ahead to advance other drugs in trials. A board and shareholder meeting is secondary - they can be part of the addon to a business deal.
Yep, so excited about the other two that I forgot. We have lots going on the next few years and lots of room to grow.
Agreed. If K data from DF showing good efficacy and we're not having even touched upon multidosing per week yet, this stock price will take off. K has potential to be quite more valuable cancer drug than what the sistership has. Add in Brilacidin and you have a big pharma bidding war.
Yes, there were. Keep up the wonderful work. You do it well.
DEFINITION of 'Confidential Treatment Order - CTO'
An order that provides confidential treatment for certain documents and information, that a company would otherwise have to file. A confidential treatment order (CTO) is issued by the Securities and Exchange Commission (SEC) and may only be in effect for a certain period of time, rather than indefinitely.
INVESTOPEDIA EXPLAINS 'Confidential Treatment Order - CTO'
Companies would typically seek a CTO in order to keep information that would otherwise put it at a disadvantage, a secret. For example, a company may apply for such an order to keep information regarding a pricing arrangement made with a partner, secret, since competitors finding out this information may go after the partner with a more competitive price.
Karin, great article about ctix. Enjoyed reading the facts, results and science of ctix compounds thru your sound judgement.
Interesting read about the posters of Brilacidin at previous infectious disease conference ECCMID 2013.
http://biotech.ulitzer.com/node/2934350
If they end up being the best, give them 3-5 more years than the other recent QDIPs.
Didn't Durata get QDIP with additional five years also?
Wish we were +8-10 yrs on the extension.
Your the oracle straight edge. You've got it measured right. God Bless.
Yes the words ideal, ovarian, pancreatic, orphan, and stage 2 caught my eyes. We shall see down the road, but it sounds like that is the direction at a minimum.
Yep, a license for B ABSSI and any more exciting news about K should easily eclipse $5.65
Thanks Karin. Maybe more DF Kevetrin data on P21 comes out soon before you write. I'm long term on this investment and glad we have many important trials this year.
if your in the area why not stop by Jorgy F2F
All I know is that a big pharma in the SF area of the conference is "The U.S. Pharmaceuticals headquarters for Roche is now Genentech in South San Francisco, CA."
At least it was not day 89
Thanks Karin, NoRetreat, sclimmuno, sclimmuno brother and incubus-now for going to the showcase and helping us so much for those who could not be there. Anyone?? Is it possible with FDA they can change protocol for phase 1 to give a two dose per week to the second highest level which is 350 mg/m2 and continue with a one dose per week at highest current level of 450 mg/m2....see what happens efficacy wise??
I was thinking they sell B for ABSSSI only and take that cash to develop the other drugs in the B platform...like the other B indications mentioned earlier (late 2014) plus the inflammatories within the B platform. If Durata got 660 million for their antibiotic what would B for ABSSSI fetch?
If they were to sell B you mean the whole platform?? And we would receive as shareholders cash and/or stock in a big company like say Pfizer. In addition, ctix would still be a company we own at our current share counts with K and P as prospects still?
Best of luck the rest of the way today to you and Karin. Thanks for your diligent time and efforts on our behalf.
We should get more news from Kevetrin regarding data from Cohort 9 on Monday. Status and dosage of cohort 10. And whether the Bologna meeting has taken place and if so when trial starts or has started. Me thinks this information is known and being saved for the Biotech Showcase.
From Nov 24 ctix headline :
The safety committee overseeing the clinical trial will be meeting in the first week of December to review safety data and discuss a possible dose escalation for the tenth cohort.
Cellceutix expects December to be a momentous month in its history. The Company anticipates that the Kevetrin trial is nearing its conclusion with the start of the tenth cohort next month. Cellceutix looks forward to additional data from the trial to add to current information that has been used to form decisions for planned Phase 2/3 trials of Kevetrin. Elsewhere, a meeting has been scheduled in December between Cellceutix and the University of Bologna to discuss the status of commencing the Phase 1/2 trial of Kevetrin in combination with cytarabine in patients with Acute Myelogenous Leukemia (AML). The Company will update shareholders on this European trial as available.
Way to lay it down. CTIX will make some noise at the April conference, find a partner in 2015 and blitz all out on CNBC about B after approval. It will be a good opportunity to talk about K also. Leo is moving well this show now in 2015 to tell later. Show then tell. He just needs to run the business of B while staying in communication with Big Pharma = the folks we'll be doing business together to market and sell B. The New York Times is not in the drug business and cannot partner with us.
Thanks for the analysis. ECCMID mtg in April 2015 is where I believe CTIX is presenting on Brilacidin. Hope we're on the NASDAQ then as the word about CTIX with first in class B and no antibiotic resistance generates a great inflow of european investors buying via NASDAQ.
Jazz Pharmaceuticals was .74 in Feb 2009. Look at it today proud and tall at 163 and some change. Your right, this guy picked the wrong fight. Patience is required here which flippers and shorts don't have. Too much going on here this year to not get financial recognition of a deal from Big Pharma. And at 90-99% short (overvalued) he claims in the article, qualifies him as a midget, the circus is waiting for him. Why does someone like this get away with such a high exaggeration?? Suggest he stick with his ABCs and don't advance to the point of creating words.
Agreed. I'm hoping Leo only uses 5 million shares at >= $9 dollars per share and ctix gets $55 million in flat cash upfront to go with it. That would give us $100 million in cash. No need to give BF anymore. They already getting a profit share of a great B platform at possibly 50/50. Hold the line Leo!! Save the other 20 million shares of shelf for 5 million share offer if news about Kevetrin is very encouraging later on. The rest of the shelf can be used for down the road 2016, 2017, 2018 as the stock price advances to 20s, 40s, 60s.... use some of the proceeds to buy back company shares, complimentary aquisitions, and more research and development and bringing to the clinic the autism drug and delpartang, whatever else etc...SOON HAPPY NEW YEAR EVERYONE.
It would be interesting to find out stock price movement over a 3-5 year period within last ten years for a biotech stock that is ranked in the top 25 of its industry for those 3-5 consecutive years. Hope we fit the bill one day. Thanks for the stats.
Thanks for all your recent posts about Vancomycin and what CTIX will design for Phase 3. Great description about current problems delivering the current King of the Hill.
Yes, we were falling to a 457 million market cap and didn't think it would hit the 400 million cap (undervalued). Too bad Leo didn't time it today to deliver the huge news during lunchtime. Then untimely news would have sunk those shorts over the past three days on a big price reversal.
I hope your right as it is that good a deal!!! Hmmm, I think he is holding the bottom line data to first get FDA confirmation as to how good this data is, how fast Phase 3 will go, and use leverage from those said points to engage in a bidding war with as many big pharmas as possible.
I'm quite happy with the stock price since beginning of December and know more news this month will propel this SP higher. I am not a trader here, riding on the backs of three fabulous drugs and chances are good we see some gamechanger success in 2015 and 2016. Thus, I am holding firm for at least those two special years of internal growth and probably much longer as the company successfully grows 5+ years out. Thanks for your charts and articles Karin. They are good reminders of solid business growth ahead!!!
Sorry Merck.
Dr Jerry, think you mean Cubist instead of Roche.
Hope we get a partner who can make good financial decisions when it comes to X billions dollars. Take your time Leo.
In the meantime, let the trials and data continue to shine.
Thank you too Dr Menon!!!
IMO Merck will not be able to buy CTIX because Menon and Leo control a a majority of the shares. And they want to internally grow this company for the next 3-5 years. Potential gamechanger drugs = high growth stock = great return on investment = greater buyout price. And one of these gamechangers is going to Phase 3 right now.
I hope Leo does not go to the NASDAQ until after Phase 3 and a license for B-ABSSI with upfront money and millions for Phase 3 approval, so the balance sheet looks like the company appears to have been profitable for some time already once it meets its birthday on NASDAQ. I think this would ensure that steady, slow, confident 3 year climb in stock price.